Post-herpetic neuralgia: a review of advances in treatment and prevention.
Post-herpetic neuralgia (PHN) is primarily a disease of the elderly and often refractory to treatment. Randomized and controlled trials have yielded several significant advances in the treatment and prevention of this disease. Treatment advances include the lidocaine patch, opioid analgesics, nortriptyline, amitriptyline, and gabapentin. However, no treatment regimen fully eliminates the pain. Improvements in prevention include prompt recognition and treatment of high-risk herpes zoster (HZ) patients with antiviral and analgesic therapies. Even with these advances, PHN remains a debilitating and painful disease. Vaccines offer the greatest promise of relief. The childhood vaccine against varicella zoster virus offers long-lasting immunity, largely preventing HZ and PHN. But most adults have already had varicella and are at risk for HZ and PHN as they age. Therefore, a more potent vaccine against varicella has been developed for use in adults. This vaccine offers a new and significant advance in the prevention of HZ and its most noteworthy complication, PHN.
Young
Lorraine
L
Department of Medicine, Dermatology Division, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, USA. lcyoung@mednet.ucla.edu
D019433:Chickenpox Vaccine / Q000627:therapeutic use; D006562:Herpes Zoster / Q000150:complications / Q000188:drug therapy; D006801:Humans; D051474:Neuralgia, Postherpetic / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
D019433:Chickenpox Vaccine